| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-09-3368 |
| P698 | PubMed publication ID | 20501621 |
| P2093 | author name string | Erik Rasmussen | |
| Anthony Tolcher | |||
| Chris H Takimoto | |||
| Patricia LoRusso | |||
| John Sarantopoulos | |||
| Alain C Mita | |||
| Leslie Wood | |||
| Monica Mita | |||
| Yu-Nien Sun | |||
| Manuel Valdivieso | |||
| Michael B Bass | |||
| Kamalesh Sankhala | |||
| NgocDiep Le | |||
| Z Don Zhong | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P1104 | number of pages | 13 | |
| P304 | page(s) | 3044-3056 | |
| P577 | publication date | 2010-05-25 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors | |
| P478 | volume | 16 |
| Q36172919 | A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival |
| Q33424270 | A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors |
| Q33996024 | A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. |
| Q31110832 | A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors |
| Q34956830 | A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours |
| Q36480124 | A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). |
| Q36671874 | A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. |
| Q36338069 | AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. |
| Q37826430 | AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q42466000 | Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method |
| Q54646109 | Antiangiogenic agents and targets: A perspective |
| Q34570079 | Antibody-based therapeutics to watch in 2011 |
| Q35536088 | Biomarkers in tumor angiogenesis and anti-angiogenic therapy |
| Q34056295 | Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee |
| Q47104935 | Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis |
| Q35836039 | Efficacy of Tie2 receptor antagonism in angiosarcoma |
| Q38757677 | Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer |
| Q37088633 | Elevated Angiopoietin-2 Level in Patients With Continuous-Flow Left Ventricular Assist Devices Leads to Altered Angiogenesis and Is Associated With Higher Nonsurgical Bleeding. |
| Q36997066 | Expression of angiopoietin-TIE system components in angiosarcoma |
| Q34230336 | Genetic polymorphism in a VEGF-independent angiogenesis gene ANGPT1 and overall survival of colorectal cancer patients after surgical resection |
| Q38109430 | Incidence and management of edema associated with trebananib (AMG 386). |
| Q35813114 | Investigation of the mechanism of clearance of AMG 386, a selective angiopoietin-1/2 neutralizing peptibody, in splenectomized, nephrectomized, and FcRn knockout rodent models |
| Q36547047 | Major clinical research advances in gynecologic cancer in 2012. |
| Q28478505 | Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil |
| Q38078400 | Monoclonal antibodies therapies for ovarian cancer |
| Q37984612 | Novel targets for VEGF-independent anti-angiogenic drugs. |
| Q38198095 | Novel therapies, including enzastaurin, in the treatment of ovarian cancer |
| Q38024765 | Overcoming resistance to antiangiogenic therapies |
| Q47229048 | Peptibodies: An elegant solution for a long-standing problem. |
| Q36503472 | Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors |
| Q48369496 | Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. |
| Q33898877 | Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma |
| Q43471758 | Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer |
| Q26991997 | Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer |
| Q35544474 | Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma |
| Q39302290 | Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis |
| Q38132231 | Targeting angiogenesis in renal cell carcinoma |
| Q38101997 | Targeting angiopoietin-2 signaling in cancer therapy |
| Q38184622 | Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. |
| Q37774852 | Targeting the ANGPT-TIE2 pathway in malignancy |
| Q28076945 | The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development |
| Q26993238 | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy |
| Q39403862 | Tumor angiogenesis and vascular normalization: alternative therapeutic targets |
| Q39393740 | Tumor angiogenesis revisited: Regulators and clinical implications. |
| Q37507440 | Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. |
Search more.